{
  "functional_evidence_assessment": [
    {
      "variant_id": {
        "Gene": "LRRK2",
        "Protein_Change": {
          "ref": "G",
          "alt": "S",
          "position": "2019"
        },
        "variant_string_id": "LRRK2 G2019S"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "Mutations in the LRRK2 gene cause late-onset PD (Parkinson's disease). The G2019S mutation moderately enhances (âˆ¼ 2-3fold) the autophosphorylation of LRRK2, as well as its ability to phosphorylate MBP (myelin basic protein).",
          "judgment": "Yes",
          "reasoning": "The paper clearly defines the disease mechanism related to LRRK2 mutations and the specific impact of the G2019S mutation on kinase activity."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "The study utilized a KESTREL screen to identify proteins phosphorylated by LRRK2, leading to the discovery that moesin is efficiently phosphorylated by LRRK2 at Thr 558. A peptide-based substrate assay was also developed.",
          "judgment": "Yes",
          "reasoning": "The assays used (KESTREL screen and peptide-based substrate assay) are appropriate for studying kinase activity and substrate phosphorylation, which are relevant to the disease mechanism.",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Step 3: Evaluate validity of specific instances of assays",
          "extracted_paper_info": "The study included controls such as kinase-inactive LRRK2 (D2017A) and used multiple replicates. The assays were validated by identifying phosphorylation sites and comparing activity of mutant forms.",
          "judgment": "Yes",
          "reasoning": "Basic controls and replicates were used, and the assays were validated through identification of phosphorylation sites and comparison of mutant activities.",
          "next_step_or_outcome": "Proceed to Sub-step 3c"
        },
        {
          "step_name": "Sub-step 3c: Variant Controls",
          "extracted_paper_info": "The study compared the activity of nine mutant forms of LRRK2, including known pathogenic and benign variants, to assess their impact on kinase activity.",
          "judgment": "Yes",
          "reasoning": "Variant controls, including known pathogenic and benign variants, were used to validate the assay results.",
          "next_step_or_outcome": "Proceed to Step 4"
        },
        {
          "step_name": "Step 4: Apply evidence to individual variant interpretation",
          "extracted_paper_info": "The G2019S mutation was shown to significantly stimulate LRRK2 autophosphorylation and phosphorylation of substrates, with a Vmax about 2.5-fold higher than non-mutated LRRK2.",
          "judgment": "Yes",
          "reasoning": "The statistical analyses and comparison of kinetic parameters (Vmax and Km) provide robust evidence for the pathogenic effect of the G2019S mutation.",
          "next_step_or_outcome": "Proceed to Sub-step 4c"
        },
        {
          "step_name": "Sub-step 4c: Correlate OddsPath",
          "extracted_paper_info": "The G2019S mutation showed a Vmax about 2.5-fold higher than non-mutated LRRK2, indicating a significant increase in kinase activity.",
          "judgment": "Yes",
          "reasoning": "The increase in Vmax suggests a high OddsPath value, supporting the pathogenic nature of the G2019S mutation.",
          "next_step_or_outcome": "Final evidence strength assessment"
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_very_strong"
      },
      "overall_conclusion": "The G2019S mutation in LRRK2 significantly increases kinase activity, as demonstrated by robust assays and statistical analyses, supporting a very strong pathogenic effect."
    },
    {
      "variant_id": {
        "Gene": "LRRK2",
        "Protein_Change": {
          "ref": "R",
          "alt": "H",
          "position": "1941"
        },
        "variant_string_id": "LRRK2 R1941H"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "Mutations in the LRRK2 gene cause late-onset PD (Parkinson's disease).",
          "judgment": "Yes",
          "reasoning": "The paper defines the disease mechanism related to LRRK2 mutations."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "The study utilized assays to measure LRRK2 kinase activity, including phosphorylation of moesin and a peptide substrate.",
          "judgment": "Yes",
          "reasoning": "The assays are appropriate for studying the impact of mutations on kinase activity.",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Step 3: Evaluate validity of specific instances of assays",
          "extracted_paper_info": "The study included controls such as kinase-inactive LRRK2 and used multiple replicates.",
          "judgment": "Yes",
          "reasoning": "Basic controls and replicates were used.",
          "next_step_or_outcome": "Proceed to Sub-step 3c"
        },
        {
          "step_name": "Sub-step 3c: Variant Controls",
          "extracted_paper_info": "The study compared the activity of multiple mutant forms of LRRK2.",
          "judgment": "Yes",
          "reasoning": "Variant controls were used to validate the assay results.",
          "next_step_or_outcome": "Proceed to Step 4"
        },
        {
          "step_name": "Step 4: Apply evidence to individual variant interpretation",
          "extracted_paper_info": "The R1941H mutation was found to be nearly inactive, displaying only marginally greater activity than the kinase-inactive LRRK2 control.",
          "judgment": "Yes",
          "reasoning": "The mutation significantly reduces kinase activity, suggesting a potential pathogenic effect through loss of function.",
          "next_step_or_outcome": "Proceed to Sub-step 4b"
        },
        {
          "step_name": "Sub-step 4b: No OddsPath Calculation",
          "extracted_paper_info": "The study did not provide statistical analyses to calculate OddsPath for the R1941H mutation.",
          "judgment": "No",
          "reasoning": "Without statistical analyses, the strength of evidence is limited by the number of variant controls used.",
          "next_step_or_outcome": "Final evidence strength assessment"
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_supporting"
      },
      "overall_conclusion": "The R1941H mutation in LRRK2 significantly reduces kinase activity, supporting a pathogenic effect, but the evidence strength is limited to supporting due to lack of statistical analyses."
    }
  ]
}